Long-Term Outcomes after Switching to Tenofovir Alafenamide in Patients with Chronic Hepatitis B

Long-Term Outcomes after Switching to Tenofovir Alafenamide in Patients with Chronic Hepatitis B

We sought to determine the long-term outcomes of chronic hepatitis B (CHB) cases switching to tenofovir alafenamide (TAF, <i>n</i> = 104, median age = 63.5 years). Data at switching to TAF (baseline) and those at 1, 2, 3, 4, and 5 years from switching to TAF were compared. At baseline, H...

Full description

Bibliographic Details
Main Authors: Tomohiro Nishikawa, Masahiro Matsui, Saori Onishi, Kosuke Ushiro, Akira Asai, Soo-Ki Kim, Hiroki Nishikawa
Format: Article
Language:English
Published: MDPI AG 2024-02-01
Series:International Journal of Molecular Sciences
Subjects:
chronic hepatitis B
tenofovir alafenamide
switch
efficacy
safety
Online Access:https://www.mdpi.com/1422-0067/25/4/2245

Internet

https://www.mdpi.com/1422-0067/25/4/2245

Similar Items